Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Confirmatory, Registrational Clinical Trial to Evaluate the Efficacy and Safety of Vincristine Sulfate LIPOSOME Injection (MARQIBO)

Next Previous
Trial Profile

A Confirmatory, Registrational Clinical Trial to Evaluate the Efficacy and Safety of Vincristine Sulfate LIPOSOME Injection (MARQIBO)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 12 Mar 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vincristine (Primary)
  • Indications Haematological malignancies; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors CASI Pharmaceuticals

Most Recent Events

  • 07 Mar 2019 According to a CASI Pharmaceuticals media release, the company is currently reviewing certain requirements provided by the Center for Drug Evaluation (CDE), a division of the NMPA, and upon satisfying those requirements, the company will commence this registration trial for MARQIBO.
  • 07 Mar 2019 According to a CASI Pharmaceuticals media release, the National Medical Products Administration (NMPA) has approved the Company's Clinical Trial Application (CTA) allowing for this registration clinical trial to evaluate the efficacy and safety of vincristine sulfate LIPOSOME injection (MARQIBO).
  • 15 Sep 2017 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top